Mohammad Reza Karimi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohammad Reza Karimi has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alireza Mirahmadizadeh
Non‐communicable Diseases Research Center Shiraz University of Medical Sciences Shiraz Iran
2 shared publications - Abdolrasool Hemmati
Department of Health Affairs Shiraz University of Medical Sciences Shiraz Iran
1 shared publication - Ali Semati
Non‐communicable Diseases Research Center Shiraz University of Medical Sciences Shiraz Iran
1 shared publication - Alireza Heiran
Shiraz University of Medical Sciences
1 shared publication - Antonio Charlys da Costa
Universidade de São Paulo
1 shared publication - Leila Moftakhar
Abadan University of medical Sciences, Abadan, Iran
1 shared publication
Latest Publications
- Open Access
- 1 March 2024
- Published by Apex Publishing in Journal of Occupational Health and Epidemiology
- Vol. 13 (1) , 1-9
The Survival Rate and Its Related Factors in Hospitalized Covid-19 Patients in Fars Province in the South of Iran: A Hospital-Based Historical Cohort Study (2019 – 2022)
- 1 March 2024
- Published by Apex Publishing in Journal of Occupational Health and Epidemiology
- Vol. 13 (1) , 1-9
Open AccessThe Survival Rate and Its Related Factors in Hospitalized Covid-19 Patients in Fars Province in the South of Iran: A Hospital-Based Historical Cohort Study (2019 – 2022)
- 23 June 2022
- Published by Wiley in Respirology
- Vol. 27 (9) , 758-766
Efficacy of single‐dose and double‐dose ivermectin early treatment in preventing progression to hospitalization in mild COVID‐19: A multi‐arm, parallel‐group randomized, double‐blind, placebo‐controlled trial
Background and objective: Ivermectin is a known anti‐parasitic agent that has been investigated as an antiviral agent against coronavirus disease 2019 (COVID‐19). This study aimed to evaluate the efficacy of ivermectin in mild COVID‐19 patients.Methods: In this multi‐arm randomized clinical trial conducted between 9 April 2021 and 20 May 2021, a total of 393 patients with reverse transcription‐PCR‐confirmed COVID‐19 infection and mild symptoms were enrolled. Subjects were randomized in a 1:1:1 ratio to receive single‐dose ivermectin (12 mg), double‐dose ivermectin (24 mg) or placebo. The primary outcome was need for hospitalization.Results: There was no significant difference in the proportion of subjects who required hospitalization between the placebo and single‐dose ivermectin groups (absolute difference in the proportions: −2.3 [95% CI = −8.5, 4.1]) and between the placebo and double‐dose ivermectin groups (absolute difference in the proportions: −3.9 [95% CI = −9.8, 2.2]). The odds of differences in mean change in severity score between single‐dose ivermectin and placebo groups (ORdifference = 1.005 [95% CI: 0.972, 1.040]; p = 0.762) and double‐dose ivermectin and placebo groups (ORdifference = 1.010 [95% CI: 0.974, 1.046]; p = 0.598) were not statistically significant. None of the six adverse events (including mild dermatitis, tachycardia and hypertension) were serious and required extra action.Conclusion: Single‐dose and double‐dose ivermectin early treatment were not superior to the placebo in preventing progression to hospitalization and improving clinical course in mild COVID‐19.
- 23 June 2022
- Published by Wiley in Respirology
- Vol. 27 (9) , 758-766
Efficacy of single‐dose and double‐dose ivermectin early treatment in preventing progression to hospitalization in mild COVID‐19: A multi‐arm, parallel‐group randomized, double‐blind, placebo‐controlled trial
Background and objective: Ivermectin is a known anti‐parasitic agent that has been investigated as an antiviral agent against coronavirus disease 2019 (COVID‐19). This study aimed to evaluate the efficacy of ivermectin in mild COVID‐19 patients.Methods: In this multi‐arm randomized clinical trial conducted between 9 April 2021 and 20 May 2021, a total of 393 patients with reverse transcription‐PCR‐confirmed COVID‐19 infection and mild symptoms were enrolled. Subjects were randomized in a 1:1:1 ratio to receive single‐dose ivermectin (12 mg), double‐dose ivermectin (24 mg) or placebo. The primary outcome was need for hospitalization.Results: There was no significant difference in the proportion of subjects who required hospitalization between the placebo and single‐dose ivermectin groups (absolute difference in the proportions: −2.3 [95% CI = −8.5, 4.1]) and between the placebo and double‐dose ivermectin groups (absolute difference in the proportions: −3.9 [95% CI = −9.8, 2.2]). The odds of differences in mean change in severity score between single‐dose ivermectin and placebo groups (ORdifference = 1.005 [95% CI: 0.972, 1.040]; p = 0.762) and double‐dose ivermectin and placebo groups (ORdifference = 1.010 [95% CI: 0.974, 1.046]; p = 0.598) were not statistically significant. None of the six adverse events (including mild dermatitis, tachycardia and hypertension) were serious and required extra action.Conclusion: Single‐dose and double‐dose ivermectin early treatment were not superior to the placebo in preventing progression to hospitalization and improving clinical course in mild COVID‐19.